Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: This phase II trial is studying how well docetaxel works in treating patients with recurrent or persistent endometrial carcinoma (cancer).
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Evaluation of Weekly Docetaxel (NSC #628503) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|
|Study Start Date:||July 2004|
|Primary Completion Date:||December 2005 (Final data collection date for primary outcome measure)|
- Determine the antitumor activity of docetaxel in patients with recurrent or persistent endometrial carcinoma.
- Determine the toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study within 10-18 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00085332
Show 75 Study Locations
|Study Chair:||Agustin Garcia, MD||Premiere Oncology|